Tumor-Agnostic Therapies: The Complex Path to Commercial Viability

How to create commercial opportunity for tumor-agnostic treatments

Executive Summary Tumor-agnostic treatments first came to market in 2017 with the revolutionary indication extension of KEYTRUDA® into microsatellite instability-high cancer Since then we have seen two more products launch: VITRAKVI® and ROZLYTREK®. While the products gained access in the USA market, the first tumor-agnostic product to be approved in Europe,…

Strategic Patient Advocacy vs. Evidence Package: The “Rare” Challenge for Orphan Drug Manufacturers

UPDATE – December 2017: After initially refusing to reimburse EXONDYS 51™, ANTHEM and EMBLEMHEALTH reversed their decisions in late 2017. While EMBLEM opted for a somewhat restrictive policy requiring patients to complete at least 300m in the 6-MWT, ANTHEM decided to cover patients as long as they are ambulatory. In their…

Page 1 of 3123